Document Detail


Xanthine oxidase inhibitor in Duchenne muscular dystrophy.
MedLine Citation:
PMID:  6896406     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The treatment with xanthine oxidase inhibitor, allopurinol, was evaluated in 17 patients with Duchenne muscular dystrophy (aged 2 years 9 months to 13 years 9 months) using the double blind technique. The total observed period was 27 months. The results of 100-point scale of graded functional abilities revealed that an improvement, unchange and progression of dysfunction were found in 2, 2 and 6 patients, respectively, in allopurinol group and in 0, 2 and 5 patients, respectively in placebo group. The patients' age and stage of the disease seemed to be related to the effectiveness or allopurinol treatment.
Authors:
H Tamari; Y Ohtani; A Higashi; S Miyoshino; I Matsuda
Related Documents :
1882906 - Comparison of sucralfate and ranitidine in the treatment of duodenal ulcers.
10815116 - Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a ra...
531516 - Cimetidine treatment of recurrent ulcer.
18346606 - Effect of preoperative oral erythromycin, erythromycin-ranitidine, and ranitidine-metoc...
8349066 - Orally administered omeprazole versus injection therapy in the prevention of rebleeding...
17161076 - Serial radionuclide angiographic assessment of left ventricular ejection fraction and r...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Brain & development     Volume:  4     ISSN:  0387-7604     ISO Abbreviation:  Brain Dev.     Publication Date:  1982  
Date Detail:
Created Date:  1982-08-26     Completed Date:  1982-08-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7909235     Medline TA:  Brain Dev     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  137-43     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Triphosphate / metabolism
Adolescent
Allopurinol / therapeutic use*
Aspartate Aminotransferases / blood
Child
Child, Preschool
Creatine Kinase / blood
Double-Blind Method
Humans
Male
Muscles / metabolism
Muscular Dystrophies / drug therapy*,  enzymology
Xanthine Oxidase / antagonists & inhibitors*
Chemical
Reg. No./Substance:
315-30-0/Allopurinol; 56-65-5/Adenosine Triphosphate; EC 1.17.3.2/Xanthine Oxidase; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.7.3.2/Creatine Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of liquid meals on duodenogastric reflux in humans.
Next Document:  Anthelmintic efficacy of ivermectin given intramuscularly in horses.